360 Results

People

  1. Lacouture
    Lacouture
  2. Panageas
    Panageas
  3. Wolchok
    Wolchok
  4. Motzer
    Motzer
  5. Postow
    Postow
  6. Houghton
    Houghton
  7. Zelenetz
    Zelenetz
  8. Balagula
    Balagula
  9. Livingston
    Livingston
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)
  7. Dermatology Service (63)
  8. GSK Faculty (53)
  9. Melanoma Disease Management Team (47)
  10. Melanoma and Immunotherapeutics Service (47)
  1. "pruritus"
Formats
  1. Journal Article (336)
  2. Review (15)
  3. Research Letter (3)
  4. Editorial (2)
  5. Miscellaneous (2)
  6. Conference Paper (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)

More Groups

People
  1. Mario Lacouture (44)
  2. Jedd Wolchok (29)
  3. Katherine Panageas (16)
  4. Paul Chapman (16)
  5. Robert Motzer (14)
  6. Michael Postow (11)

More People

Years
  1. 2025 (11)
  2. 2024 (38)
  3. 2023 (28)
  4. 2022 (12)
  5. 2021 (16)
  6. 2020 (24)

More Years

Publications
  1. Lancet Oncology (30)
  2. Clinical Cancer Research (17)
  3. Journal of Clinical Oncology (17)
  4. Cancer (11)
  5. Journal of the American Academy of Dermatology (11)
  6. Annals of Oncology (9)

More Publications

Publishers
  1. Elsevier Inc. (46)
  2. Elsevier Science, Inc. (39)
  3. Springer (26)
  4. Nature Publishing Group (22)
  5. American Association for Cancer Research (20)
  6. American Society of Clinical Oncology (18)

More Publishers

Results (360)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
    Journal Article

    Algazi, A. P.; Esteve-Puig, R.; Nosrati, A.; Hinds, B.; Hobbs-Muthukumar, A.; Nandoskar, P.; Ortiz-Urda, S.; Chapman, P. B.; Daud, A.
    Pigment Cell & Melanoma Research (2018)

    Fulltext@MSK | Save
  • Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
    Journal Article

    Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Interventional endoscopy in the diagnosis and management of pancreatic adenocarcinoma
    Journal Article

    Khokhar, A. S.; Sher, A. F.; Schattner, M.
    Chinese Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Delayed dermatitis following injury caused by coral
    Journal Article

    MenkinSmith, L. P.; Marchetti, M. A.; Krywko, D. M.
    Journal of Emergency Medicine (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
    Journal Article

    Momtaz, P.; Harding, J. J.; Ariyan, C.; Coit, D. G.; Merghoub, T.; Gasmi, B.; You, D.; Viale, A.; Panageas, K. S.; Samoila, A.; more...
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma
    Journal Article

    Sznol, M.; Ferrucci, P. F.; Hogg, D.; Atkins, M. B.; Wolter, P.; Guidoboni, M.; Lebbé, C.; Kirkwood, J. M.; Schachter, J.; Daniels, G. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
    Journal Article

    Puzanov, I.; Diab, A.; Abdallah, K.; Bingham, C. O. 3rd; Brogdon, C.; Dadu, R.; Hamad, L.; Kim, S.; Lacouture, M. E.; LeBoeuf, N. R.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study
    Journal Article

    Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E. R.; Hahn, N. M.; de Wit, R.; Pang, L.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and safety of pembrolizumab in patients enrolled in KEYNOTE-030 in the United States: An expanded access program
    Journal Article

    Gangadhar, T. C.; Hwu, W. J.; Postow, M. A.; Hamid, O.; Daud, A.; Dronca, R.; Joseph, R.; O'Day, S. J.; Hodi, F. S.; Pavlick, A. C.; more...
    Journal of Immunotherapy (2017)

    Fulltext@MSK | Save